HEALTH CARE
<i> Times Staff and Wire Reports</i>
Rhone-Poulenc Seeks OK of Drug: The Collegeville, Pa.-based pharmaceutical company said it submitted a new-drug application to the Food and Drug Administration after two clinical trials showed Rilutek to be effective in treating Lou Gehrig’s disease, technically known as amyotrophic lateral sclerosis, or ALS. The neuromuscular disease attacks nerve cells in the brain and spinal cord, resulting in muscle paralysis and respiratory failure.
Start your day right
Sign up for Essential California for news, features and recommendations from the L.A. Times and beyond in your inbox six days a week.
You may occasionally receive promotional content from the Los Angeles Times.
